Home >

Welcome to Molecular Oncology Tumor Boards

The Molecular Oncology Tumor Boards are a series of bi-monthly, user-driven discussions designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies. Moderated by an expert pathologist and medical oncologist, each case will be updated with new information over a 2-week period as user comments are added. Sign in with your ASCO username and password to participate. After 2 weeks, the discussion will be locked to further commentary and users will be able to claim CME credit for their participation. Visit ASCO University to learn more. 

To participate in discussions on other oncology-related topics, visit ASCO’s member community on myConnection. Connect with colleagues, build your professional network, exchange ideas, collaborate, and more

LOGIN TO START A DISCUSSION
Molecular Oncology Tumor Board
ASCO University
Oct 14, 2015 10:22 AM
Read more to answer the following questions: 1. In general, would you be more inclined to offer a targeted therapy regimen or an immune therapy regimen? 2. If a BRAF-targeted therapy approach is selected, what therapeutic options are the most appropriate? 3. If an immune-targeted therapy approach...
Molecular Oncology Tumor Board
ASCO University
Sep 09, 2015 9:57 AM
Read more to answer the following questions: 1) What is the differential diagnosis of skin rashes that precede or accompany a diagnosis of acute myeloid leukemia?  What particular dermatological condition does this patient have?  How would you treat it? 2) What is the prognostic significance of the...
Molecular Oncology Tumor Board
ASCO University
Aug 12, 2015 9:39 AM
Read more to answer the following questions: 1) What tumor types should be considered in the differential diagnosis of a CK7+ CK20- CUP? 2)Could you have performed additional immunohistochemical stains to try to determine the site of origin? 3) Is EML4-ALK fusion unique to lung adenocarcinomas? 4) ...
Molecular Oncology Tumor Board
ASCO University
Jul 15, 2015 10:53 AM
Read more to answer the following questions: 1.) What is the role of Arv7 in the resistance to hormonal therapy? 2.) What are the potential treatment implications of patient who possess the ARV7 splice variant? 3.) What is the role of ArV7 in the response to cytotoxic agents such as docetaxel?

 
Molecular Oncology Tumor Board
ASCO University
Jun 10, 2015 9:50 AM
Read more to answer the following: 1) What are the most important prognostic features for this type of ovarian cancer at diagnosis? 2)How would you classify this patient: sensitive or resistant to platinum-based chemotherapy?  Provide your definition of platinum resistance. 3)What would be your...

Pages


Advertisement